Press Release: Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program

Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be the first disease-modifying therapy to delay the progression of stage 3 T1D in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1DTzield is also being reviewed under the accelerated approval program Paris, October 20, 2025. The US Food and Drug Administration (FDA) has accepted for exped ...